Research

Breast cancer is the leading cause of cancer death in women worldwide. Although many BC can be successfully treated when early detected, high aggressive and metastatic breast cancer, unresponsive to hormonal therapies has higher recurrence and lower survival rates due to the lack of efficient and specific therapies. Most treatments for cancer controlling present low therapeutic indices and a wide spectrum of severe side-effects, in part due to the little or no selectivity of drugs for cancer cells over non-tumoral cells. To overcome this limitation, we are developing new ruthenium-peptide conjugates based on ruthenium organometallic complexes conjugated to peptides that bind selectively to receptors overexpressed at the cancer cell surfaces in order to selective delivery of ruthenium drugs to cancer cells.